Actively Recruiting
ENX-205 SAD/PET Study in Healthy Adults
Led by Engrail Therapeutics INC · Updated on 2026-04-21
60
Participants Needed
1
Research Sites
53 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a two-part study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and receptor occupancy (RO) of ENX-205 in healthy adult participants in a double-blind placebo-controlled, single ascending dose (SAD) study (Part 1) and an open-label, single-dose, positron emission tomography (PET) study (Part 2).
CONDITIONS
Official Title
ENX-205 SAD/PET Study in Healthy Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biologically female participants who are not pregnant, lactating, or breastfeeding
- Female participants of non-childbearing potential (permanently sterilized and with a negative pregnancy test) OR female participants of childbearing potential in Part 1 willing to follow birth control restrictions and with a negative pregnancy test
- Biologically male participants assigned male at birth, who if fertile, agree to follow birth control restrictions and refrain from sperm donation
- Age 18 to 65 years
- Healthy adult participants
You will not qualify if you...
- Unable or unwilling to comply with study requirements
- Considered by Investigator or Sponsor as unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Parexel London EPCU
London, Middlesex, United Kingdom, HA1 3UJ
Actively Recruiting
Research Team
E
Eve M Taylor, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here